<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603356</url>
  </required_header>
  <id_info>
    <org_study_id>OSI-930-103</org_study_id>
    <nct_id>NCT00603356</nct_id>
  </id_info>
  <brief_title>Phase I Study of OSI-930 and Erlotinib in Cancer Tumors</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of Daily Oral OSI-930 and Erlotinib (Tarceva) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, open-label, phase 1, dose escalation study to determine the maximum tolerated&#xD;
      dose of OSI-930 and Erlotinib.&#xD;
&#xD;
      Patients may continue to receive OSI-930 and Erlotinib until one of the following occurs:&#xD;
      disease progression, adverse event requiring withdrawal, failure to recover from toxicity&#xD;
      despite a 14-day dosing interruption, medical or ethical reasons, patient request, or patient&#xD;
      death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD), evaluate the pharmacokinetic profiles</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, evaluate pharmacodynamic relationships</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSI-930 and erlotinib</intervention_name>
    <description>OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histology or cytologically documented malignancy that is now advanced and/or&#xD;
             metastatic and refractory to established forms of therapy or for which no effective&#xD;
             therapy exists&#xD;
&#xD;
          -  Age greater than or equal to 18 years&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
          -  ANC greater than or equal to 1.5 x 10^9/L&#xD;
&#xD;
          -  Bilirubin less than or equal to 1.5 x upper limit of normal (ULN), AST and ALT less&#xD;
             than or equal to 2.5 x ULN&#xD;
&#xD;
          -  Creatinine less than or equal to 1.5 ULN&#xD;
&#xD;
          -  Predicted life expectancy greater than or equal to 12 weeks&#xD;
&#xD;
          -  Prior chemotherapy is permitted provided that a minimum of 3 weeks has elapsed&#xD;
&#xD;
          -  Prior tyrosine kinase inhibitor therapy is permitted&#xD;
&#xD;
          -  Patients must have recovered from any treatment-related toxicities (with some&#xD;
             exceptions) prior to registration&#xD;
&#xD;
          -  Prior hormonal therapy is permitted provided it is discontinued prior to registration&#xD;
             (with the exception of prostate cancer patients who have been on hormone therapy for&#xD;
             at least 3 months)&#xD;
&#xD;
          -  Prior radiation therapy is permitted provided that it did not exceed 25% of bone&#xD;
             marrow reserve and patients have recovered from the toxic effects (a minimum of 21&#xD;
             days must have elapsed unless the radiotherapy was palliative and nonmyelosuppressive)&#xD;
&#xD;
          -  Prior surgery is permitted, provided that wound healing has occurred prior to&#xD;
             registration&#xD;
&#xD;
          -  Patients must use proactive effective contraceptive measures throughout the study&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
          -  Accessible for repeat dosing and follow-up&#xD;
&#xD;
          -  Adequate hematopoietic, hepatic, and renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant cardiac disease unless well controlled&#xD;
&#xD;
          -  Current or former smokers, unless patients stopped smoking greater than 3 months prior&#xD;
             to registration&#xD;
&#xD;
          -  Active or uncontrolled infections of serious illnesses or medical conditions that&#xD;
             could interfere with participation&#xD;
&#xD;
          -  History of unacceptable toxicity with previous EGFR inhibitor therapy&#xD;
&#xD;
          -  History of any psychiatric condition that might impair the patient's ability to&#xD;
             provide informed consent or participate&#xD;
&#xD;
          -  Use of CYP3A4 inducers/inhibitors during the 14 days prior to first dose&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
          -  Symptomatic brain metastases which are not stable, require steroids, are potentially&#xD;
             life-threatening or that have required radiation within the last 28 days&#xD;
&#xD;
          -  History of allergic reaction attributed to a similar compound as study drug&#xD;
&#xD;
          -  GI abnormalities including inability to take oral medications, required for IV&#xD;
             alimentation&#xD;
&#xD;
          -  Clinically significant ophthalmologic abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <last_update_submitted>September 26, 2011</last_update_submitted>
  <last_update_submitted_qc>September 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GIST</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Mesothelioma</keyword>
  <keyword>Renal</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

